EMERGE is a global, randomized, multicenter, placebo-controlled Phase 3 trial that will evaluate claseprubart 300mg/2mL S.C. dosed Q2W and Q4W vs. placebo, with top-line results anticipated in 2H’28 ...
VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced the initiation of cell line development for ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A Boynton Beach private club has ...
At the same time, VIS-101 is also an important driver, and I apologise for now focusing on it too much. It provides a second leg to the story here, with a Phase 2b initiation expected sometime in 2H26 ...
Secure Ad Serving (HTTPS): All third-party served creatives and their components (images, stylesheets, JavaScript, tracking pixels, etc.) must be secure (HTTPS) to ensure compliance and correct ...
Customer stories Events & webinars Ebooks & reports Business insights GitHub Skills ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results